Type 2 diabetes patients who used canagliflozin as an add-on to metformin/sulfonylurea treatment showed better A1C levels and body weight at 52 weeks than those who took sitagliptin, according to a study in Diabetes Care. Researchers also found 47.6% of canagliflozin-treated patients attained an A1C of less than 7%, compared with 35.3% in the sitagliptin group.

Related Summaries